New England Journal of Medicine· 2020Q1· Clinical trial

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman et al.

2,803citations
Q1SCImago
2020year

Short summary

Adding venetoclax to azacitidine significantly improved survival and remission rates in older or co-morbid patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine